The strength of extensive preclinical data [21,22,43,52,54,57,58] supporting the antitumor activity of TLR-9 agonists in many solid tumors prompted us to investigate their tolerability and therapeutic potential in cancer patients, either as single agent treatment, then in combination with standard chemotherapies or cancer vaccines (Table 1). The gene discussed is TLR9; the disease is cancer.